|
π
|
Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
37 auth.
C. Bowden,
A. Brugger,
A. Swann,
J. Calabrese,
P. Janicak,
F. Petty,
S. Dilsaver,
John M. Davis,
A. Rush,
J. Small,
E. Garza-TreviΓ±o,
S. Risch,
P. Goodnick,
D. Morris,
V. Shu,
...
P. B. Johnson,
M. Blake,
M. Javors,
L. Ereshefsky,
T. McLeod,
A. Shoaib,
Mark H. Johnson,
S. Kimmel,
A. Wesley,
R. Qualtiere,
C. Trivedi,
J. Javaid,
J. Peterson,
M. Lambert,
M. Zielinski,
P. Orsulak,
L. Sharp,
L. Akers,
M. C. Miller,
J. Kellams,
G. C. Woodham,
A. Frazer
|
9 |
1994 |
9
π
|
|
π
|
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS Ξ²-amyloid in animal models and in Alzheimerβs disease patients
24 auth.
M. Kennedy,
A. Stamford,
Xia Chen,
K. Cox,
J. Cumming,
M. Dockendorf,
Mike F. Egan,
L. Ereshefsky,
R. Hodgson,
Lynn A. Hyde,
...
S. Jhee,
H. Kleijn,
R. Kuvelkar,
Wei Li,
B. A. Mattson,
H. Mei,
J. Palcza,
Jack D. Scott,
M. Tanen,
M. Troyer,
J. Tseng,
J. Stone,
E. Parker,
M. Forman
|
8 |
2016 |
8
π
|
|
π
|
Robust Central Reduction of Amyloid-Ξ² in Humans with an Orally Available, Non-Peptidic Ξ²-Secretase Inhibitor
25 auth.
P. May,
R. Dean,
S. Lowe,
F. MartΓ©nyi,
S. Sheehan,
L. Boggs,
S. Monk,
B. M. Mathes,
Dustin J Mergott,
B. Watson,
S. Stout,
D. Timm,
Elizabeth Smith Labell,
C. Gonzales,
M. Nakano,
...
S. Jhee,
M. Yen,
L. Ereshefsky,
T. Lindstrom,
D. Calligaro,
Patrick J. Cocke,
D. Greg Hall,
S. Friedrich,
Martin Citron,
J. Audia
|
8 |
2011 |
8
π
|
|
π
|
Defining and assessing adherence to oral antipsychotics: a review of the literature.
7 auth.
D. Velligan,
Y. Lam,
D. Glahn,
J. Barrett,
N. Maples,
L. Ereshefsky,
...
Alexander L. Miller
|
8 |
2005 |
8
π
|
|
π
|
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
19 auth.
Alexander L. Miller,
Catherine S. Hall,
R. Buchanan,
P. Buckley,
J. Chiles,
R. Conley,
M. Crismon,
L. Ereshefsky,
S. Essock,
M. Finnerty,
...
S. Marder,
Del D. Miller,
J. McEvoy,
A. Rush,
S. Saeed,
N. Schooler,
S. Shon,
S. Stroup,
Bernardo Tarin-Godoy
|
8 |
2007 |
8
π
|
|
π
|
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
21 auth.
Alexander L. Miller,
Catherine S. Hall,
R. Buchanan,
P. Buckley,
J. Chiles,
R. Conley,
M. Crismon,
L. Ereshefsky,
L. Ereshefsky,
S. Essock,
...
S. Essock,
M. Finnerty,
S. Marder,
Del D. Miller,
J. McEvoy,
A. Rush,
S. Saeed,
N. Schooler,
S. Shon,
S. Stroup,
Bernardo Tarin-Godoy
|
8 |
2004 |
8
π
|
|
π
|
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
21 auth.
Alexander L. Miller,
Catherine S. Hall,
R. Buchanan,
P. Buckley,
J. Chiles,
R. Conley,
M. Crismon,
L. Ereshefsky,
L. Ereshefsky,
S. Essock,
...
S. Essock,
M. Finnerty,
S. Marder,
Del D. Miller,
J. McEvoy,
A. Rush,
S. Saeed,
N. Schooler,
S. Shon,
S. Stroup,
Bernardo Tarin-Godoy
|
8 |
2004 |
8
π
|
|
π
|
Relationships among subjective and objective measures of adherence to oral antipsychotic medications.
9 auth.
D. Velligan,
Mei Wang,
P. Diamond,
D. Glahn,
D. Castillo,
S. Bendle,
...
Y. Lam,
L. Ereshefsky,
Alexander L. Miller
|
7 |
2007 |
7
π
|
|
π¦
|
Pharmacokinetics and drug interactions: update for new antipsychotics.
L. Ereshefsky
|
7 |
1996 |
7
π¦
|
|
π
|
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
10 auth.
D. Velligan,
P. Diamond,
J. Mintz,
N. Maples,
Xueying Li,
J. Zeber,
...
L. Ereshefsky,
Yui-wing F Lam,
D. Castillo,
Alexander L. Miller
|
7 |
2007 |
7
π
|
|
π
|
What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
14 auth.
A. Kemp,
N. Schooler,
A. Kalali,
L. Alphs,
R. Anand,
G. Awad,
M. Davidson,
S. DubΓ©,
L. Ereshefsky,
G. Gharabawi,
...
A. Leon,
J. LΓ©pine,
S. Potkin,
A. Vermeulen
|
7 |
2008 |
7
π
|
